At a Glance
- Company: 20n Bio
- Funding: US$7.5 million Seed+ round
- Backer: Strategic industry investor
- Focus area: Cyclic peptide discovery and AI-enabled workflows
- Next steps: Scale the platform and advance discovery programmes
What happened?
20n Bio has closed a US$7.5 million Seed+ financing round to support its biotechnology platform. The round was led by a strategic industry investor and is intended to help the company strengthen its high-throughput cyclic peptide discovery capabilities.
Why does it matter?
Cyclic peptides can offer advantages over traditional small molecules, including stronger target binding and potentially improved selectivity. By combining that chemistry with AI, 20n Bio is aiming to speed up hit discovery and improve the odds of finding drug-like candidates.
Who’s behind it?
20n Bio is a biotechnology company focused on peptide discovery and platform-enabled drug development. The new financing brings in a strategic investor, which suggests the company’s technology has relevance not just for research, but also for industry partnerships.
How was it achieved?
The company plans to use the funds to expand a high-throughput discovery engine for cyclic peptides and integrate artificial intelligence into the workflow. In practice, that means using software and automation to help identify and prioritise molecules more efficiently.
What’s next?
20n Bio is expected to use the capital to build out its platform, refine AI-assisted discovery and progress internal programmes toward more validated drug candidates. The financing should also help position the company for future partnering or a larger growth round.